[
    {
        "question": "How does EVRENZO benefit patients with anaemia of CKD?",
        "answer": "EVRENZO harnesses the HIF pathway to promote acoordinated erythropoietic response",
        "choices": [
            "EVRENZO is an erythropoiesis-stimulating agent (ESA)",
            "EVRENZO is an oral iron supplement",
            "EVRENZO harnesses the HIF pathway to promote acoordinated erythropoietic response",
            "EVRENZO stimulates production of hepcidin"
        ]
    },
    {
        "question": "What effect does EVRENZO have on haemoglobin levels?",
        "answer": "EVRENZO is comparable to ESA in helping patients to achieve and maintain target Hb",
        "choices": [
            "EVRENZO is comparable to ESA in helping patients to achieve and maintain target Hb",
            "EVRENZO is comparable to placebo and inferior to ESA in achieving and maintaining target Hb ",
            "EVRENZO achieves haemoglobin levels of 8â€“10 g/dL in patients with anaemia of CKD "
        ]
    },
        {
        "question": "What effect does EVRENZO have on use of IV iron in patients not on dialysis with anaemia of CKD?",
        "answer": "Fewer patients treated with EVRENZO used <br /> IV iron than those on ESA",
        "choices": [
            "EVRENZO increases the requirement for IV iron <br /> compared to ESA",
            "EVRENZO reduces serum iron levels regardless of iron supplementation",
            "EVRENZO makes no difference to the requirement for IV iron",
            "Fewer patients treated with EVRENZO used <br /> IV iron than those on ESA"
        ]
    },
    {
        "question": "In patients with NDD- and IDD-CKD, how does the cardiovascular safety profile of EVRENZO compare with ESA?",
        "answer": "EVRENZO does not increase the risk of CV events in NDD and IDD patients compared to ESA",
        "choices": [
            "EVRENZO increases the risk of CV events compared with ESA",
            "EVRENZO does not increase the risk of CV events in NDD and IDD patients compared to ESA",
            "EVRENZO increases the risk of all-cause mortality but not MACE compared with ESA",
            "Cardiovascular safety has not yet been studied in this group"
        ]
    },
    {
        "question": "How can the mode of administration of EVRENZO benefit patients?",
        "answer": "EVRENZO is an oral treatment with no special storage instructions that can be taken at home",
        "choices": [
            "EVRENZO is a subcutaneous injection given once a week",
            "EVRENZO is an intravenous infusion that should be administered in hospital",
            "EVRENZO is an oral treatment that must be stored in refrigerated conditions",
            "EVRENZO is an oral treatment with no special storage instructions that can be taken at home"
        ]
    },
    {
        "question": "What is the dosing regimen of EVRENZO?",
        "answer": "EVRENZO should be taken three times a week (TIW), on <br /> non-consecutive days",
        "choices": [
            "EVRENZO should be taken twice daily (BD), after meals",
            "EVRENZO should be taken three times a week (TIW), on <br /> non-consecutive days",
            "EVRENZO should be taken every day",
            "EVRENZO should be taken immediately after haemodialysis"
        ]
    }
]